|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Lyme Disease | |||||
| Lyme Neuroborreliosis | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Borrelia Infections | |||||
| 3 | More general conditions related to this trial | ||||
| Bacterial Infections | |||||
| Central Nervous System Bacterial Infections | |||||
| Central Nervous System Diseases | |||||
| Central Nervous System Infections | |||||
| Gram-Negative Bacterial Infections | |||||
| Nervous System Diseases | |||||
| Spirochaetales Infections | |||||
| Tick-Borne Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| ceftriaxone | |||||
| 5 | More general drug interventions related to this trial | ||||
| Anti-Bacterial Agents | |||||
| Anti-Infective Agents | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| National Institute of Neurological Disorders and Stroke (NINDS) | |||||